Clinical trialsCereno widens clinical program as competition heats up in lung diseaseSwedish biotech Cereno Scientific today announced the expansion of its clinical development program for its investigational small-molecule therapy, CS014, targeting rare lung diseases. more ➔
RestructuringPoxel takes first step in recovery plan with €5 million equity lineFrench biotech Poxel is trying to stabilise its business after judicial reorganisation, with its court-approved recovery plan now moving into the execution phase. The Lyon-based company, which has spent … more ➔
Sartorius AGSartoriusSartorius returns to a path of profitable growth in 2025The Göttingen-based life science group Sartorius AG closed the 2025 financial year, based on preliminary figures, with a marked increase in revenue and earnings. Group sales grew by 7.6% at constant … more ➔
Licence agreementKahimmune launches and secures exclusive license for dark-genome cancer vaccine platformNewly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify … more ➔
Photo: Carolina Garcia Tavizon, via Unsplash NeuroscienceOrigami and Ipsen join forces on protein degradation in neuroscienceFrench biopharmaceutical company Ipsen has entered a global collaboration and option agreement with San Diego-based biotech Origami Therapeutics to advance a small-molecule protein degrader program targeting … more ➔
©FabienMalotYearly results Sanofi ends 2025 on a high, but trims R&D prioritiesParis-based drugmaker Sanofi closed 2025 with strong growth and upbeat guidance, but its latest results also reveal sharp pipeline cuts that underline a tougher phase for R&D choices. more ➔
Lonza GroupCDMOCDMOs dominate the headlines – and Lonza delivers a clear message of strengthCDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined … more ➔
Vetter PharmaCDMOVetter: a multi-million-euro investment for new CDMO facility boost for Saarland/GermanyWith an initial investment of around €480 million, Ravensburg-based Vetter Pharma has now fleshed out its plans to expand operations in Saarlouis, Saarland. The former automotive site is to be redeveloped … more ➔
International Journal of Molecular Sciences, doi: 10.3390/ijms17040561 JO - sAntibody drug conjugatesAfter a turbulent phase: a new milestone from Takeda for Heidelberg PharmaPositive signals from a partnership with Takeda are allowing Heidelberg Pharma to push the setback from a milestone payment not received as planned from Telix somewhat into the background. Nevertheless, … more ➔
Market accessTenpoint wins FDA approval for presbyopia eye drop and raises $235 millionIt’s a busy day for U.K.-based Tenpoint Therapeutics, which has secured U.S. Food and Drug Administration (FDA) approval for YUVEZZI, a combination eye drop for the treatment of presbyopia, while raising … more ➔
Sartorius AG
Photo: Carolina Garcia Tavizon, via Unsplash 
©FabienMalot
Lonza Group
Vetter Pharma
International Journal of Molecular Sciences, doi: 10.3390/ijms17040561 JO - s